Skip to main content
. 2015 Mar 26;125(19):3024–3031. doi: 10.1182/blood-2015-01-623991

Figure 1.

Figure 1

Overall outcomes of NMA haplo BMT with high-dose posttransplantation cyclophosphamide. (A) Progression-free and overall survival. (B-D) Cumulative incidences by competing-risk analysis of relapse and nonrelapse mortality (B), acute graft-versus-host disease (C), and any chronic graft-versus-host disease (D). Point estimates are provided in Table 2.